|
Characteristics of the patients. |
||||
| Characteristics |
Training group |
Validation Group 1 – HCV before treatment |
Validation Group 2 – HCV sustained responders |
Validation Group 3 – Alcoholic liver disease |
|
|
||||
| Number of patients |
310 |
171 |
201 |
62 |
| Age at biopsy, years |
48.9 (12.4) |
44.1 (7.2) |
43.6 (8.0) |
46.6 (9.8) |
| Male |
201 (65%) |
111 (65%) |
122 (61%) |
47/62 (76%) |
| Female |
109 (35%) |
60 (35%) |
79 (39%) |
15 (24%) |
| BMI, kg/m2 |
25.4 (5.1) |
27.7 (5.0) |
26.5 (4.8) |
24.2 (4.1) |
| Biopsy quality |
||||
| Length |
17.0 (6.2) |
16.6 (15.5) |
17.0 (8.2) |
13.5 (6.8) |
| Length ≥ 15 mm |
205 (67%) |
82 (48%) |
96 (48%) |
15 (24%) |
| Number of fragments |
2.5 (2.3) |
- |
- |
1.9 (1.6) |
| One fragment |
128/278 (46%) |
- |
- |
37 (60%) |
| Duration biopsy-serum, mean (days range) |
1 (0–30) |
40 (0–90) |
11 (0–45) |
7 (0–14) |
| Liver Risk factor |
||||
| HCV |
211 (68%) |
171 (100%) |
0 (0%) |
0 (0%) |
| HBV |
18 (6%) |
0 (0%) |
0 (0%) |
0 (0%) |
| NAFLD |
69 (22%) |
0 (0%) |
0 (0%) |
0 (0%) |
| ALD |
12 (4%) |
0 (0%) |
0 (0%) |
0 (0%) |
| Daily alcohol = 50 g/day |
34/236 (14%) |
0 (0%) |
0 (0%) |
62 (100%) |
| Cured HCV infection |
0 (0%) |
0 (0%) |
201 (100%) |
0 (0%) |
| Metabolic factor |
||||
| BMI ≥ 27.0 |
92 (30%) |
88 (51%) |
77 (38%) |
14 (23%) |
| Glucose ≥ 6.0 mmol/L |
63 (20%) |
30 (18%) |
27 (13%) |
20 (32%) |
| Triglycerides ≥ 1.7 mmol/L |
67 (22%) |
36 (21%) |
54 (27%) |
20 (32%) |
| Cholesterol ≥ 6.0 mmol/L |
61 (20%) |
12 (7%) |
26 (13%) |
23 (37%) |
| Metabolic factor: number per patient |
||||
| None |
132 (43%) |
60 (35%) |
96 (48%) |
17 (27%) |
| One |
101 (33%) |
64 (37%) |
72 (36%) |
20 (32%) |
| Two |
52 (17%) |
39 (23%) |
31 (15%) |
19 (31%) |
| Three |
22 (7%) |
8 (5%) |
0 (0%) |
5 (8%) |
| Four |
3 (1%) |
0 (0%) |
2 (1%) |
1 (2%) |
| Liver steatosis grade |
||||
| None (0%) |
130 (42%) |
58 (34%) |
116 (58%) |
2 (3%) |
| Mild (Score 1–5%) |
40 (13%) |
68 (40%) |
63 (31%) |
2 (3%) |
| Moderate (Score 6–33%) |
69 (22%) |
35 (20%) |
17 (8%) |
42 (68%) |
| Marked (Score 34–66%) |
36 (12%) |
7 (4%) |
4 (3%) |
12 (19%) |
| Severe (Score 67–100%) |
35 (11%) |
3 (2%) |
1 (0.5%) |
4 (7%) |
| Liver fibrosis stage at biopsy |
||||
| F0 – No fibrosis |
62 (20%) |
0 (0%) |
16 (8%) |
8 (13%) |
| F1 – Fibrosis without septa |
127 (41%) |
102 (60%) |
136 (68%) |
23 (37%) |
| F2 – Few septa |
52 (17%) |
39 (23%) |
33 (16%) |
11 (18%) |
| F3 – Many septa |
36 (11%) |
19 (11%) |
9 (4%) |
7 (11%) |
| F4 – Cirrhosis |
33 (11%) |
11 (6%) |
7 (3%) |
13 (21%) |
| Markers (normal range) |
||||
| AST, IU/L (17–27 female; 20–32 male) |
83 (159) |
82 (57) |
23 (9) |
89 (83) |
| ALT, IU/L (11–26 female; 16–35 male) |
109 (114) |
118 (94) |
19 (10) |
72 (88) |
| Total bilirubin, mol/L (1–21) |
14.8 (26.2) |
11.1 (4.8) |
8.8 (4.6) |
21.5 (19.6) |
| GGT, U/L (7–32 female; 11–49 male) |
112 (183) |
84 (96) |
21 (18) |
323 (443) |
| A2M, g/L (female 1·6-4·0; male 1·4-3·3) |
2.4 (1.0) |
3.1 (1.2) |
2.0 (0.8) |
1.8 (0.5) |
| ApoA1 g/L (1·2-1·7) |
1.4 (0.3) |
1.3 (0.3) |
1.2 (0.3) |
1.5 (0.5) |
| Haptoglobin, g/L (0·35-2·00)* |
0.95 (0.57) |
0.78 (0.45) |
0.86 (0.43) |
1.39 (0.63) |
| Glucose, mmol/L |
5.5 (3.2) |
5.4 (1.2) |
5.3 (1.0) |
5.8 (1.6) |
| Cholesterol, mmol/L |
4.9 (1.3) |
4.5 (1.0) |
5.0 (1.0) |
5.4 (1.9) |
| Triglycerides, mmol/L |
1.5 (1.4) |
1.4 (0.8) |
1.6 (1.0) |
1.9 (3.1) |
| FibroTest |
0.42 (0.28) |
0.47 (0.26) |
0.29 (0.20) |
0.43 (0.28) |
| SteatoTest |
0.49 (0.25) |
0.53 (0.22) |
0.36 (0.22) |
0.58 (0.25) |
|
Data are mean (SD) or proportion. BMI = body mass index; HCV = hepatitis C virus; HBV = hepatitis B virus; NAFLD = non-alcoholic fatty liver disease; ALD = alcoholic liver disease; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = γ-glutamyl transpeptidase; A2M = α2-macroglobulin; ApoA1 = apolipoprotein A1. | ||||
Poynard et al. Comparative Hepatology 2005 4:10 doi:10.1186/1476-5926-4-10 |
||||